-
Product Name
Ladiratuzumab vedotin reference antibody
- Documents
-
Description
Anti-LIV-1 / SLC39A6 Antibody (Ladiratuzumab vedotin)
-
Tested applications
ELISA
-
Species reactivity
Human LIV-1 / SLC39A6
-
Isotype
IgG1
-
Preparation
Recombinant expression and purified from CHO cells.
-
Clonality
Monoclonal
-
Formulation
0.1 M Pro-Ac, 20 mM Arg, pH 5.0
-
Storage instructions
-80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.
-
Validations
SDS-PAGE
Anti-LIV-1 / SLC39A6 Antibody (Ladiratuzumab vedotin) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
SEC-HPLC
The purity of Anti-LIV-1 / SLC39A6 Antibody (Ladiratuzumab vedotin) is 98.2%, determined by SEC-HPLC.
Bioactivity: ELISA
Immobilized human LIV 1, His Tag at 2 ug/mL can bind Anti-LIV-1 / SLC39A6 Antibody (Ladiratuzumab vedotin), EC50 is 0.007652 ug/mL.
Bioactivity: FACS
Human LIV1 CHOS cells were stained with Anti-LIV-1 / SLC39A6 Antibody (Ladiratuzumab vedotin) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50 is 0.07456 ug/mL.
Function: Cytotoxicity
The killing ratio Ladiratuzumab vedotin by Human LIV-1 HEK293 Cell Line increased with the increase of antibody concentration, and the killing Rate (%) reached 74%
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"